TransMedics Group’s (TMDX) “Hold” Rating Reiterated at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports.

TMDX has been the topic of several other reports. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Baird R W raised TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Oppenheimer decreased their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Piper Sandler decreased their target price on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday, November 20th. Finally, JPMorgan Chase & Co. dropped their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Stock Performance

Shares of TMDX traded down $7.68 on Tuesday, reaching $77.46. 592,770 shares of the stock traded hands, compared to its average volume of 999,196. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of 90.58 and a beta of 2.06. The stock’s 50-day moving average price is $110.21 and its 200-day moving average price is $135.81. TransMedics Group has a 12 month low of $68.84 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the firm posted ($0.12) EPS. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. Equities analysts forecast that TransMedics Group will post 1.01 EPS for the current fiscal year.

Insider Activity

In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,958 shares of company stock worth $3,470,328 over the last 90 days. 7.00% of the stock is owned by company insiders.

Institutional Trading of TransMedics Group

A number of hedge funds have recently bought and sold shares of the company. Comerica Bank boosted its position in shares of TransMedics Group by 1,072.5% during the first quarter. Comerica Bank now owns 14,422 shares of the company’s stock valued at $1,066,000 after buying an additional 13,192 shares during the last quarter. Cetera Advisors LLC purchased a new position in TransMedics Group during the 1st quarter worth $392,000. Harbor Capital Advisors Inc. lifted its holdings in shares of TransMedics Group by 311.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 6,048 shares of the company’s stock valued at $911,000 after buying an additional 4,578 shares during the period. SG Americas Securities LLC raised its holdings in shares of TransMedics Group by 886.9% during the second quarter. SG Americas Securities LLC now owns 21,189 shares of the company’s stock valued at $3,191,000 after acquiring an additional 19,042 shares during the last quarter. Finally, Capital CS Group LLC purchased a new position in TransMedics Group in the second quarter worth approximately $659,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.